{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:42:34Z","timestamp":1793241754878,"version":"4.5.0"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Glioma, particularly glioblastoma (GBM), remains one of the most lethal primary brain tumors, characterized by aggressive biological behavior, profound intratumoral heterogeneity, and a highly immunosuppressive tumor microenvironment. Despite encouraging advances in cancer immunotherapy, durable clinical benefit from glioma vaccines has remained limited, highlighting a substantial translational gap between early immunogenicity and long-term therapeutic efficacy. In this review, we provide an integrative overview of current glioma vaccine strategies, including peptide-based, dendritic cell\u2013based, nucleic acid\u2013based, and autologous tumor-derived platforms, with a particular focus on their biological rationale, clinical performance, and translational limitations. Rather than merely summarizing recent developments, we critically examine the shared factors that have constrained clinical success, including antigen heterogeneity, immune escape, HLA restriction, treatment-related immunosuppression, and the inhibitory effects of the glioma tumor microenvironment. We further discuss how these challenges have shaped the emerging rationale for combination strategies involving vaccines with chemotherapy, anti-angiogenic agents, immune checkpoint blockade, and other immunotherapeutic modalities. Finally, we highlight forward-looking design principles for next-generation glioma vaccines, including improved antigen selection, biomarker-guided patient stratification, microenvironment-aware therapeutic design, and more predictive translational models. Overall, we propose that future progress in glioma vaccine therapy will depend not only on improving vaccine platforms themselves, but also on integrating them into biologically rational and clinically informed therapeutic frameworks.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1781820","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:31:09Z","timestamp":1778477469000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging frontiers in glioma therapy: the evolving role of glioma vaccines"],"prefix":"10.3389","volume":"17","author":[{"given":"Renfei","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Shanghai Changhai Hospital, Naval Medical University","place":["Shanghai, China"]},{"name":"State Key Laboratory of Vaccines for Infectious Diseases, Department of Laboratory Medicine, National Innovation Platform for Industry-Education Intergration in Vaccine Research, School of Public Health, Xiamen University","place":["Xiamen, China"]},{"name":"Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, National Innovation Platform for Industry-Education Intergration in Vaccine Research, School of Public Health, Xiamen University","place":["Xiamen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery\/Neuro-Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"He","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Shanghai Changhai Hospital, Naval Medical University","place":["Shanghai, China"]},{"name":"State Key Laboratory of Vaccines for Infectious Diseases, Department of Laboratory Medicine, National Innovation Platform for Industry-Education Intergration in Vaccine Research, School of Public Health, Xiamen University","place":["Xiamen, China"]},{"name":"Xiang An Biomedicine Laboratory, Department of Laboratory Medicine, National Innovation Platform for Industry-Education Intergration in Vaccine Research, School of Public Health, Xiamen University","place":["Xiamen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongluo","family":"Jiang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Department of Nuclear Medicine, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]},{"name":"Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Department of Nuclear Medicine, Sun Yat-sen University Cancer Center","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery\/Neuro-Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Shanghai Changhai Hospital, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s13046-020-01778-6","article-title":"Clinical implication of cellular vaccine in glioma: current advances and future prospects","volume":"39","author":"Yan","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bas.2025.104277","article-title":"Double fluorescence-guided surgery with 5-ALA and fluorescein sodium in grade 2 and grade 3 adult-type diffuse gliomas: retrospective analysis of 112 cases","volume":"5","author":"Bianconi","year":"2025","journal-title":"Brain Spine"},{"key":"B3","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s10143-024-03052-1","article-title":"A novel scoring system proposal to guide surgical treatment indications for high grade gliomas in elderly patients: DAK-75","volume":"47","author":"Bianconi","year":"2024","journal-title":"Neurosurg Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.603911","article-title":"Current immunotherapies for glioblastoma multiforme","volume":"11","author":"Huang","year":"2020","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.578877","article-title":"Immune checkpoint targeted therapy in glioma: status and hopes","volume":"11","author":"Qi","year":"2020","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.omto.2020.06.019","article-title":"CD133 mRNA-loaded dendritic cell vaccination abrogates glioma stem cell propagation in humanized glioblastoma mouse model","volume":"18","author":"Do","year":"2020","journal-title":"Mol Ther Oncolytics"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.122924","article-title":"Nucleic acid immunotherapeutics and vaccines: a promising approach to glioblastoma multiforme treatment","volume":"638","author":"Dain","year":"2023","journal-title":"Int J Pharm"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1453-3","article-title":"Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma","volume":"62","author":"Vik-Mo","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20069","article-title":"Exciting new advances in neuro-oncology: the avenue to a cure for Malignant glioma","volume":"60","author":"Van Meir","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"B13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/labinvest.2017.19","article-title":"Immune microenvironment of gliomas","volume":"97","author":"Gieryng","year":"2017","journal-title":"Lab Invest"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7150\/thno.38147","article-title":"Nanocarrier-based drug combination therapy for glioblastoma","volume":"10","author":"Zhao","year":"2020","journal-title":"Theranostics"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1188\/16.cjon.s1.2-8","article-title":"Glioblastoma: overview of disease and treatment","volume":"20","author":"Davis","year":"2016","journal-title":"Clin J Oncol Nurs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3978\/j.issn.2305-5839.2015.05.10","article-title":"Current trends in the surgical management and treatment of adult glioblastoma","volume":"3","author":"Young","year":"2015","journal-title":"Ann Transl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae144.263","article-title":"Immunotherapeutic advances in glioma management: the rise of vaccine-based approaches","volume":"30","author":"Andrew Awuah","year":"2024","journal-title":"CNS Neurosci Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3322\/caac.21613","article-title":"Management of glioblastoma: state of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1038\/s41467-020-18569-4","article-title":"Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression","volume":"11","author":"De Boeck","year":"2020","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-023-01579-1","article-title":"mRNA vaccines in disease prevention and treatment","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cells10020265","article-title":"Immunotherapy of glioblastoma: current strategies and challenges in tumor model development","volume":"10","author":"Majc","year":"2021","journal-title":"Cells"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2024.06.009","article-title":"Vaccine-based immunotherapy and related preclinical models for glioma","volume":"30","author":"Yao","year":"2024","journal-title":"Trends Mol Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104963","article-title":"Glioblastoma vaccines: past, present, and opportunities","volume":"100","author":"Xiong","year":"2024","journal-title":"EBioMedicine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217601","article-title":"Advancing glioblastoma therapy: learning from the past and innovations for the future","volume":"617","author":"Rana","year":"2025","journal-title":"Cancer Lett"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-11-3358","article-title":"Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein","volume":"19","author":"Crane","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-014-1676-y","article-title":"Peptide vaccines for the treatment of glioblastoma","volume":"123","author":"Swartz","year":"2015","journal-title":"J Neuro-Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.12932\/AP-120520-0841","article-title":"Recent developments in neoantigen-based cancer vaccines","volume":"38","author":"Hodge","year":"2020","journal-title":"Asian Pac J Allergy Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1172\/jci163449","article-title":"Next-generation antigen-presenting cell immune therapeutics for gliomas","volume":"133","author":"Lee-Chang","year":"2023","journal-title":"J Clin Invest"},{"key":"B29","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.ctrv.2013.05.007","article-title":"Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme","volume":"39","author":"Bregy","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108929","article-title":"Dendritic cell vaccines for glioblastoma fail to complete clinical translation: bottlenecks and potential countermeasures","volume":"109","author":"Li","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.672508","article-title":"Making a cold tumor hot: the role of vaccines in the treatment of glioblastoma","volume":"11","author":"Frederico","year":"2021","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad088","article-title":"Dendritic cell vaccine trials in gliomas: untangling the lines","volume":"25","author":"Hotchkiss","year":"2023","journal-title":"Neuro Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02616","article-title":"Vaccines targeting gliomas: antigens matter","volume":"41","author":"Platten","year":"2023","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12967-018-1507-6","article-title":"First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma","volume":"16","author":"Liau","year":"2018","journal-title":"J Transl Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1084\/jem.186.7.1177","article-title":"Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors","volume":"186","author":"Ashley","year":"1997","journal-title":"J Exp Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9030244","article-title":"An overview on the development of mRNA-based vaccines and their formulation strategies for improved antigen expression in vivo","volume":"9","author":"Rahman","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41467-025-67331-1","article-title":"mRNA vaccine developed for sequential selective organ-to-cell targeting of glioma","volume":"17","author":"Shi","year":"2025","journal-title":"Nat Commun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-017-0045-7","article-title":"Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies","volume":"37","author":"An","year":"2018","journal-title":"Oncogene"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1092587","article-title":"EGFR(vIII): an oncogene with ambiguous role","volume":"2019","author":"Rutkowska","year":"2019","journal-title":"J Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-22-0201","article-title":"A novel EGFRvIII T-cell bispecific antibody for the treatment of glioblastoma","volume":"21","author":"Iurlaro","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-09-0347","article-title":"Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients","volume":"69","author":"Lu","year":"2009","journal-title":"Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/febs.12393","article-title":"The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered","volume":"280","author":"Gan","year":"2013","journal-title":"FEBS J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-185-7_22","article-title":"Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and Malignant gliomas","volume":"55","author":"Wikstrand","year":"1995","journal-title":"Cancer Res"},{"key":"B44","article-title":"Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII","volume":"57","author":"Wikstrand","year":"1997","journal-title":"Cancer Res"},{"key":"B45","article-title":"Analysis of the phosphatidylinositol 3\u2019-kinase signaling pathway in glioblastoma patients in vivo","volume":"63","author":"Choe","year":"2003","journal-title":"Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-11-0124","article-title":"Oncogenic EGFR signaling activates an mTORC2-NF-\u03baB pathway that promotes chemotherapy resistance","volume":"1","author":"Tanaka","year":"2011","journal-title":"Cancer Discov"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.944452","article-title":"Advances in immunotherapy for glioblastoma multiforme","volume":"13","author":"Mahmoud","year":"2022","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13046-022-02349-7","article-title":"Emerging therapies for glioblastoma: current state and future directions","volume":"41","author":"Rong","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/febs.13668","article-title":"Immune checkpoint blockade in lymphoid Malignancies","volume":"283","author":"Thanarajasingam","year":"2016","journal-title":"FEBS J"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00345-8","article-title":"The foundations of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/cmi.2014.83","article-title":"The origin and function of tumor-associated macrophages","volume":"12","author":"Liu","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30517-x","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-1140","article-title":"Rindopepimut with Bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial","volume":"26","author":"Reardon","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00996","article-title":"Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma","volume":"41","author":"Ahluwalia","year":"2023","journal-title":"J Clin Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not203","article-title":"Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial","volume":"16","author":"Bloch","year":"2014","journal-title":"Neuro Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy200","article-title":"A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma","volume":"21","author":"Narita","year":"2019","journal-title":"Neuro Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-0506","article-title":"A Cancer Research UK first time in human phase I trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma","volume":"22","author":"Rampling","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03363-z","article-title":"A vaccine targeting mutant IDH1 in newly diagnosed glioma","volume":"592","author":"Platten","year":"2021","journal-title":"Nature"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02555-6","article-title":"A H3K27M-targeted vaccine in adults with diffuse midline glioma","volume":"29","author":"Grassl","year":"2023","journal-title":"Nat Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"22355","DOI":"10.1038\/s41598-021-01707-3","article-title":"A phase I study of the WT2725 dosing emulsion in patients with advanced Malignancies","volume":"11","author":"Fu","year":"2021","journal-title":"Sci Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-0261","article-title":"A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma","volume":"25","author":"Wen","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"344","DOI":"10.21203\/rs.3.rs-2117699\/v1","article-title":"Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed glioblastoma patients: safety and efficacy assessment","volume":"41","author":"Bota","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-3805","article-title":"Phase Ib clinical trial of IGV-001 for patients with newly diagnosed glioblastoma","volume":"27","author":"Andrews","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3171\/2014.5.jns132392","article-title":"Phase I\/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma","volume":"121","author":"Ishikawa","year":"2014","journal-title":"J Neurosurg"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153901","article-title":"Clinical applications of immunotherapy for recurrent glioblastoma in adults","volume":"15","author":"Olivet","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B67","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/imr.12773","article-title":"CAR T cells for brain tumors: lessons learned and road ahead","volume":"290","author":"Akhavan","year":"2019","journal-title":"Immunol Rev"},{"key":"B68","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41419-021-03568-0","article-title":"Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects","volume":"12","author":"Wang","year":"2021","journal-title":"Cell Death Dis"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1255611","article-title":"Immunotherapy: a promising approach for glioma treatment","volume":"14","author":"Yasinjan","year":"2023","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2478\/jtim-2018-0025","article-title":"Nanotechnology for treatment of glioblastoma multiforme","volume":"6","author":"Michael","year":"2018","journal-title":"J Transl Int Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.02.039IF:42.5Q1","article-title":"Advances in cancer immunotherapies","volume":"186","author":"Dagher","year":"2023","journal-title":"Cell"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","author":"Lim","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","article-title":"Brain immunology and immunotherapy in brain tumours","volume":"20","author":"Sampson","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox182","article-title":"Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma","volume":"20","author":"Bielamowicz","year":"2018","journal-title":"Neuro Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: a phase 1 dose-escalation trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0510-9","article-title":"Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma","volume":"57","author":"Ciesielski","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0845-x","article-title":"Antitumor cytotoxic T-cell response induced by a survivin peptide mimic","volume":"59","author":"Ciesielski","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1890-x","article-title":"Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent Malignant glioma","volume":"65","author":"Fenstermaker","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox036.071","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202502901r","article-title":"The application of PD-1 inhibitors in immunotherapy for glioblastoma","volume":"40","author":"Dong","year":"2026","journal-title":"FASEB J"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-2500","article-title":"Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma","volume":"27","author":"Nayak","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00709-6","article-title":"Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial","volume":"5","author":"Bagley","year":"2024","journal-title":"Nat Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107419","article-title":"Clinical investigation of CAR T cells for solid tumors: lessons learned and future directions","volume":"205","author":"Bagley","year":"2020","journal-title":"Pharmacol Ther"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B88","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41392-024-01824-1","article-title":"Combination therapy with oncolytic virus and T cells or mRNA vaccine amplifies antitumor effects","volume":"9","author":"Fu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.11.008","article-title":"Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy","volume":"34","author":"White","year":"2023","journal-title":"Ann Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1781820\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:31:12Z","timestamp":1778477472000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1781820\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":92,"alternative-id":["10.3389\/fimmu.2026.1781820"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1781820","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"article-number":"1781820"}}